- Home
- AMS vs PHGE Comparison
AMS vs PHGE Comparison
Compare AMS & PHGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMS
- PHGE
- Stock Information
- Founded
- AMS 1980
- PHGE 2015
- Country
- AMS United States
- PHGE Israel
- Employees
- AMS N/A
- PHGE N/A
- Industry
- AMS Medical Specialities
- PHGE Biotechnology: Pharmaceutical Preparations
- Sector
- AMS Health Care
- PHGE Health Care
- Exchange
- AMS Nasdaq
- PHGE Nasdaq
- Market Cap
- AMS 14.7M
- PHGE 13.0M
- IPO Year
- AMS N/A
- PHGE N/A
- Fundamental
- Price
- AMS $2.10
- PHGE $0.39
- Analyst Decision
- AMS
- PHGE Strong Buy
- Analyst Count
- AMS 0
- PHGE 1
- Target Price
- AMS N/A
- PHGE $15.00
- AVG Volume (30 Days)
- AMS 26.1K
- PHGE 1.3M
- Earning Date
- AMS 11-11-2025
- PHGE 11-12-2025
- Dividend Yield
- AMS N/A
- PHGE N/A
- EPS Growth
- AMS N/A
- PHGE N/A
- EPS
- AMS N/A
- PHGE N/A
- Revenue
- AMS $29,251,000.00
- PHGE N/A
- Revenue This Year
- AMS $5.06
- PHGE N/A
- Revenue Next Year
- AMS N/A
- PHGE N/A
- P/E Ratio
- AMS N/A
- PHGE N/A
- Revenue Growth
- AMS 26.61
- PHGE N/A
- 52 Week Low
- AMS $2.01
- PHGE $0.34
- 52 Week High
- AMS $3.59
- PHGE $1.16
- Technical
- Relative Strength Index (RSI)
- AMS 36.94
- PHGE 25.21
- Support Level
- AMS $2.02
- PHGE $0.55
- Resistance Level
- AMS $2.38
- PHGE $0.61
- Average True Range (ATR)
- AMS 0.09
- PHGE 0.05
- MACD
- AMS -0.02
- PHGE -0.02
- Stochastic Oscillator
- AMS 22.22
- PHGE 3.84
About AMS American Shared Hospital Services
American Shared Hospital Services provides stereotactic radiosurgery equipment, Advanced radiation therapy, and related equipment. It currently provides Gamma Knife units to medical centers and stand-alone facilities. The company, along with its subsidiaries, operates through the following operations: Gamma Knife, Advanced Radiation Therapy Equipment and Services, and Proton Beam Radiation Therapy Operations. It generates most of its revenue from the domestic market.
About PHGE BiomX Inc. COmmon Stock
BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).